Delivery Order SPE2DR25D2100-SPE2DR26FA1FH
- Not listed
- The Defense Logistics Agency awarded a $1,754.28 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 2, 2026, for the supply of Hemangeol 4.28 mg/ml oral solution (120 ml). The contract, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of January 26, 2026. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution (120ml) under a firm fixed-price contract with a ceiling value of $2,662.56. This is a competitive award with no set-aside designation, and performance is scheduled for completion by December 29, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution in a 120ml quantity, with a contract ceiling value of $1,775.04. This competitively awarded, firm fixed-price delivery order is expected to be completed by December 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution in a 120 ml unit at a firm fixed price of $1,263.27. This is an unset-aside, competitively awarded delivery order with an ultimate completion date of June 25, 2025, to be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with...
- The Defense Logistics Agency awarded a delivery order valued at $2,631.42 to AmerisourceBergen Drug Corp for the supply of Hemangeol 4.28 mg/ml oral solution (120 ml) on January 15, 2026, with an ultimate completion date of February 6, 2026. This is a firm fixed-price, non-set-aside contract with performance at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Hemangeol 4.28 mg/ml oral solution in 120ml quantities, with a contract ceiling value of $1,263.24 and firm fixed pricing. This competitively awarded, non-set-aside delivery order is scheduled for completion by November 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of...
- The Defense Logistics Agency awarded a $10,106.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Hemangeol 4.28 mg/mL oral solution (120 mL) on August 29, 2025, with completion targeted for September 22, 2025. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the prescription medication Hemangeol (4.28 mg/ml oral solution, 120 ml). The contract has a firm fixed price of $1,263.27 and a performance period that extends through May 23, 2025. This contract is not designated as a set-aside and is therefore open to competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,656.80 to Amerisourcebergen Drug Corp, a subsidiary of the for-profit company Cencora, Inc. doing business as Amerisourcebergen. The contract is for the delivery of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product, with a completion date of March 26, 2024. This award is associated with a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, valued at up...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of HEMANGEOL 4.28 MG/ML ORAL SOLN 120ML, a pharmaceutical product, with a potential value of $1,242.60 and a completion date of March 5, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division located in Conshohocken, Pennsylvania, is the prime contractor on this award. The contract...
- SPE2DR25D2100Indefinite Delivery Contract
- SPE2DR25D2100-SPE2DR26FA1FHDelivery Order
On January 15, 2026, the Defense Logistics Agency awarded a delivery order valued at $1,315.71 to AmerisourceBergen Drug Corp for the supply of Hemangeol 4.28 mg/mL oral solution (120 mL). This firm fixed-price delivery order, with an ultimate completion date of February 6, 2026, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The work will be performed at the company's Conshohocken facility. This delivery order is issued under AmerisourceBergen's parent company, Cencora, Inc. (doing business as AmerisourceBergen), which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031. This prime contract vehicle enables the supply of a comprehensive range of pharmaceutical products and medical supplies—including specialty medications, brand-name and generic drugs, vaccines, and medical devices—to support military healthcare programs globally. The current order for Hemangeol, a medication used in the treatment of infantile hemangioma, exemplifies the specialized pharmaceutical commodities provided through this strategic partnership with the Defense Logistics Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 1/14/26 |